Sustained HIV Suppression With Co-formulated Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in a Person With Transmitted Dolutegravir Resistance and Pretreatment Resistance to Lamivudine: a Case Report From HPTN 083
Hannah P. Moore(Johns Hopkins University), Susan H. Eshleman(Johns Hopkins University), Amber Moser(Johns Hopkins University), Beatriz Grinsztejn(Fundação Oswaldo Cruz), John W. Mellors(Textron Systems (United Kingdom)), Michael Seisa(LabCorp (United States)), Christos J. Petropoulos(IGM Biosciences (United States)), Raphael J. Landovitz(APLA Health), Marybeth McCauley(Family Health International 360), James F. Rooney(Gilead Sciences (United States)), Elias K. Halvas(University of Pittsburgh), Javier Valencia-Huamaní(Asociación Civil Impacta Salud y Educación), Mark A. Marzinke(Family Health International 360), Urvi M. Parikh(University of Pittsburgh), Alex R. Rinehart, Lydia Soto-Torres, Amelia L Price(Johns Hopkins University), Kerri J. Penrose(University of Pittsburgh), Zhe Wang(Tsinghua University), Jessica M. Fogel(Johns Hopkins University)
Cited by 0
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
|New England Journal of Medicine|2015|1.6k